| abstract |
The present invention relates to benzimidazole derivatives having the general formula I and their use for the treatment of diseases, in particular for the treatment of inflammatory diseases, cancer, stroke and/or Alzheimer's, wherein n is 0 or 1; X 1 and X 2 are, at each occurrence, independently CR 5 or N; Y is C 1 -C 6 alkylene, wherein the alkylene is optionally substituted with one to two C 1 -C 3 alkyl groups; R 1 is selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkoxy, -NH 2 , -NHR 6 , -NR 7 R 8 and -NH-(R 9 ) n -R 10 where n is 0 or 1 is; R 2 is selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, -NH 2 , -NHR 6 , -NR 7 R 8 and the group -NH-(R 9 ) n -R 10 where n is 0 or 1; is; R 3 is hydrogen, hydroxyl, OR 11 , -NR 7 R 8 , C 1 -C 6 alkoxy, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, C 1 -C 3 haloalkyl, -C( O) NHR 11 , aryl, heteroaryl and heterocyclyl groups, wherein each cycloalkyl, aryl, heteroaryl, and heterocyclyl is optionally and independently substituted with one to four R a groups; ; R 4 is -NH 2 , -N(R 12 )(V) p R 13 , -NH(V) p -OR 14 , -NHC(O)R 15 and selected from the group consisting of the groups of Formula Ia shown below. |